transferrin receptor 1 tfr1 Search Results


bi-specific antibody (tfr  (Denali Therapeutics)
90
Denali Therapeutics bi-specific antibody (tfr
Current and emerging delivery strategies to enhance <t>antibody</t> penetration in the brain. The blood–brain barrier (BBB), composed of endothelial cells (BECs), the acellular basement membrane, pericytes and astrocytic end-feet, shields the brain microenvironment from foreign materials in the blood, including administered biotherapeutics. Strategies to overcome the BBB and enhance the delivery of biotherapeutics, particularly mAbs, include: (1) <t>Bi-specific</t> antibodies. Conjugation of a therapeutic antibody to an antibody or ligand specific to an RMT receptor (e.g., transferrin receptor <t>(TfR)</t> or insulin receptor (IR)) results in endocytosis, allowing the antibody to traverse across the BBB and then engage its CNS target within the brain parenchyma. (2) Focused ultrasound in combination with the intravenous injection of gas-filled lipid shell microbubbles (MBs) imparts a mechanical force upon the brain endothelium, inducing increased vesicle formation within BECs and disruption of tight junctions between BECs, allowing peripherally administered antibodies to cross the BBB through vesicle-mediated transcytosis and paracellular transport, respectively. (3) Nanoparticles describe a range of nanoscale drug delivery vehicles including liposomes (20–1000 nm), gold nanoparticles (Au NPs) (1–150 nm) and dendrimers (2–10 nm). Antibodies can be conjugated to the outer surface of the nanoparticle. In addition, nanoparticles can be conjugated with targeting ligands and polyethylene glycol (PEG) to mediate efficient transcytosis across the BBB and site-specific targeting. These nanoparticles have been demonstrated to cross the BBB via receptor-mediated transcytosis, transmembrane diffusion, and carrier-mediated transport. (4) Exosomes can be loaded with proteins and have been shown to cross the BBB through its interaction with heparan sulfate proteoglycans on the surface of BECs, resulting in endocytosis and subsequent transcytosis across the BBB. This is an emerging strategy and could be used to encapsulate therapeutic antibody fragments or nanobodies in the future; (5) Adeno-associated virus (AAV). Viral vectors encoding protein/antibody genes and packaged into BBB-crossing AAV serotypes likely cross the BBB through glycoprotein-mediated transcytosis (akin to RMT), subsequently resulting in neuronal transduction and expression of protein/antibody genes. This approach would be especially useful for intracellular protein targets. Created with BioRender.com.
Bi Specific Antibody (Tfr, supplied by Denali Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bi-specific antibody (tfr/product/Denali Therapeutics
Average 90 stars, based on 1 article reviews
bi-specific antibody (tfr - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
monoclonal antibodies for defying of proteins were against transferrin receptor 1 (tfr1)  (Bioworld Antibodies)
90
Bioworld Antibodies monoclonal antibodies for defying of proteins were against transferrin receptor 1 (tfr1)
Current and emerging delivery strategies to enhance <t>antibody</t> penetration in the brain. The blood–brain barrier (BBB), composed of endothelial cells (BECs), the acellular basement membrane, pericytes and astrocytic end-feet, shields the brain microenvironment from foreign materials in the blood, including administered biotherapeutics. Strategies to overcome the BBB and enhance the delivery of biotherapeutics, particularly mAbs, include: (1) <t>Bi-specific</t> antibodies. Conjugation of a therapeutic antibody to an antibody or ligand specific to an RMT receptor (e.g., transferrin receptor <t>(TfR)</t> or insulin receptor (IR)) results in endocytosis, allowing the antibody to traverse across the BBB and then engage its CNS target within the brain parenchyma. (2) Focused ultrasound in combination with the intravenous injection of gas-filled lipid shell microbubbles (MBs) imparts a mechanical force upon the brain endothelium, inducing increased vesicle formation within BECs and disruption of tight junctions between BECs, allowing peripherally administered antibodies to cross the BBB through vesicle-mediated transcytosis and paracellular transport, respectively. (3) Nanoparticles describe a range of nanoscale drug delivery vehicles including liposomes (20–1000 nm), gold nanoparticles (Au NPs) (1–150 nm) and dendrimers (2–10 nm). Antibodies can be conjugated to the outer surface of the nanoparticle. In addition, nanoparticles can be conjugated with targeting ligands and polyethylene glycol (PEG) to mediate efficient transcytosis across the BBB and site-specific targeting. These nanoparticles have been demonstrated to cross the BBB via receptor-mediated transcytosis, transmembrane diffusion, and carrier-mediated transport. (4) Exosomes can be loaded with proteins and have been shown to cross the BBB through its interaction with heparan sulfate proteoglycans on the surface of BECs, resulting in endocytosis and subsequent transcytosis across the BBB. This is an emerging strategy and could be used to encapsulate therapeutic antibody fragments or nanobodies in the future; (5) Adeno-associated virus (AAV). Viral vectors encoding protein/antibody genes and packaged into BBB-crossing AAV serotypes likely cross the BBB through glycoprotein-mediated transcytosis (akin to RMT), subsequently resulting in neuronal transduction and expression of protein/antibody genes. This approach would be especially useful for intracellular protein targets. Created with BioRender.com.
Monoclonal Antibodies For Defying Of Proteins Were Against Transferrin Receptor 1 (Tfr1), supplied by Bioworld Antibodies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal antibodies for defying of proteins were against transferrin receptor 1 (tfr1)/product/Bioworld Antibodies
Average 90 stars, based on 1 article reviews
monoclonal antibodies for defying of proteins were against transferrin receptor 1 (tfr1) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Current and emerging delivery strategies to enhance antibody penetration in the brain. The blood–brain barrier (BBB), composed of endothelial cells (BECs), the acellular basement membrane, pericytes and astrocytic end-feet, shields the brain microenvironment from foreign materials in the blood, including administered biotherapeutics. Strategies to overcome the BBB and enhance the delivery of biotherapeutics, particularly mAbs, include: (1) Bi-specific antibodies. Conjugation of a therapeutic antibody to an antibody or ligand specific to an RMT receptor (e.g., transferrin receptor (TfR) or insulin receptor (IR)) results in endocytosis, allowing the antibody to traverse across the BBB and then engage its CNS target within the brain parenchyma. (2) Focused ultrasound in combination with the intravenous injection of gas-filled lipid shell microbubbles (MBs) imparts a mechanical force upon the brain endothelium, inducing increased vesicle formation within BECs and disruption of tight junctions between BECs, allowing peripherally administered antibodies to cross the BBB through vesicle-mediated transcytosis and paracellular transport, respectively. (3) Nanoparticles describe a range of nanoscale drug delivery vehicles including liposomes (20–1000 nm), gold nanoparticles (Au NPs) (1–150 nm) and dendrimers (2–10 nm). Antibodies can be conjugated to the outer surface of the nanoparticle. In addition, nanoparticles can be conjugated with targeting ligands and polyethylene glycol (PEG) to mediate efficient transcytosis across the BBB and site-specific targeting. These nanoparticles have been demonstrated to cross the BBB via receptor-mediated transcytosis, transmembrane diffusion, and carrier-mediated transport. (4) Exosomes can be loaded with proteins and have been shown to cross the BBB through its interaction with heparan sulfate proteoglycans on the surface of BECs, resulting in endocytosis and subsequent transcytosis across the BBB. This is an emerging strategy and could be used to encapsulate therapeutic antibody fragments or nanobodies in the future; (5) Adeno-associated virus (AAV). Viral vectors encoding protein/antibody genes and packaged into BBB-crossing AAV serotypes likely cross the BBB through glycoprotein-mediated transcytosis (akin to RMT), subsequently resulting in neuronal transduction and expression of protein/antibody genes. This approach would be especially useful for intracellular protein targets. Created with BioRender.com.

Journal: Pharmaceutics

Article Title: Current and Emerging Strategies for Enhancing Antibody Delivery to the Brain

doi: 10.3390/pharmaceutics13122014

Figure Lengend Snippet: Current and emerging delivery strategies to enhance antibody penetration in the brain. The blood–brain barrier (BBB), composed of endothelial cells (BECs), the acellular basement membrane, pericytes and astrocytic end-feet, shields the brain microenvironment from foreign materials in the blood, including administered biotherapeutics. Strategies to overcome the BBB and enhance the delivery of biotherapeutics, particularly mAbs, include: (1) Bi-specific antibodies. Conjugation of a therapeutic antibody to an antibody or ligand specific to an RMT receptor (e.g., transferrin receptor (TfR) or insulin receptor (IR)) results in endocytosis, allowing the antibody to traverse across the BBB and then engage its CNS target within the brain parenchyma. (2) Focused ultrasound in combination with the intravenous injection of gas-filled lipid shell microbubbles (MBs) imparts a mechanical force upon the brain endothelium, inducing increased vesicle formation within BECs and disruption of tight junctions between BECs, allowing peripherally administered antibodies to cross the BBB through vesicle-mediated transcytosis and paracellular transport, respectively. (3) Nanoparticles describe a range of nanoscale drug delivery vehicles including liposomes (20–1000 nm), gold nanoparticles (Au NPs) (1–150 nm) and dendrimers (2–10 nm). Antibodies can be conjugated to the outer surface of the nanoparticle. In addition, nanoparticles can be conjugated with targeting ligands and polyethylene glycol (PEG) to mediate efficient transcytosis across the BBB and site-specific targeting. These nanoparticles have been demonstrated to cross the BBB via receptor-mediated transcytosis, transmembrane diffusion, and carrier-mediated transport. (4) Exosomes can be loaded with proteins and have been shown to cross the BBB through its interaction with heparan sulfate proteoglycans on the surface of BECs, resulting in endocytosis and subsequent transcytosis across the BBB. This is an emerging strategy and could be used to encapsulate therapeutic antibody fragments or nanobodies in the future; (5) Adeno-associated virus (AAV). Viral vectors encoding protein/antibody genes and packaged into BBB-crossing AAV serotypes likely cross the BBB through glycoprotein-mediated transcytosis (akin to RMT), subsequently resulting in neuronal transduction and expression of protein/antibody genes. This approach would be especially useful for intracellular protein targets. Created with BioRender.com.

Article Snippet: Bi-specific antibody (TfR) , DNL310 (Enzyme transport vehicle-Iduronate-2-sulfatase fusion, ETV:IDS) , Mucopolysaccharidosis Type II (Hunter syndrome) , Denali Therapeutics Inc. , Phase 1/2 , Recruiting , NCT04251026.

Techniques: Conjugation Assay, Injection, Diffusion-based Assay, Transduction, Expressing

Strategies that have enhanced therapeutic antibody delivery to the brain.

Journal: Pharmaceutics

Article Title: Current and Emerging Strategies for Enhancing Antibody Delivery to the Brain

doi: 10.3390/pharmaceutics13122014

Figure Lengend Snippet: Strategies that have enhanced therapeutic antibody delivery to the brain.

Article Snippet: Bi-specific antibody (TfR) , DNL310 (Enzyme transport vehicle-Iduronate-2-sulfatase fusion, ETV:IDS) , Mucopolysaccharidosis Type II (Hunter syndrome) , Denali Therapeutics Inc. , Phase 1/2 , Recruiting , NCT04251026.

Techniques: In Vitro

Current delivery strategies in clinical trials.

Journal: Pharmaceutics

Article Title: Current and Emerging Strategies for Enhancing Antibody Delivery to the Brain

doi: 10.3390/pharmaceutics13122014

Figure Lengend Snippet: Current delivery strategies in clinical trials.

Article Snippet: Bi-specific antibody (TfR) , DNL310 (Enzyme transport vehicle-Iduronate-2-sulfatase fusion, ETV:IDS) , Mucopolysaccharidosis Type II (Hunter syndrome) , Denali Therapeutics Inc. , Phase 1/2 , Recruiting , NCT04251026.

Techniques: